Clinical Trials - March 25, 2026
Verigraft initiates Phase II/III trial of its personalized tissue engineered vein
The company has announced the initiation of a pivotal Phase II/III trial of its P-TEV (personalized tissue engineered vein) in patients with chronic venous insufficiency (CVI), supported by USD 10 million from existing investors.
Clinical Trials - March 23, 2026
BioArctic presents new data on long-term, real-world treatment with lecanemab
BioArctic’s partner Eisai presented the data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held in Copenhagen, Denmark March 17-21.
Clinical Trials - March 20, 2026
Lundbeck advances Parkinson’s research with new Phase 1b data
The company has presented new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity.
Clinical Trials - March 15, 2026
Oslo University Hospital begins study with TikoMed’s drug candidate
Oslo University Hospital has begun the inclusion of patients in the IMPACT study, which aims to investigate the efficacy and safety of TikoMed’s candidate drug ILB compared to riluzole for the treatment of ALS.
Clinical Trials - March 9, 2026
Oncopeptides secures fast-track designation for Window-of-Opportunity study
Oncopeptides has achieved key regulatory agreement with both the Swedish and Norwegian Medical Products Agencies regarding the design of its planned “Window-of-Opportunity” study evaluating a Peptide Drug Conjugate (PDC) in glioblastoma.
Clinical Trials - February 10, 2026
Lundbeck presents real-world data highlighting improvements in migraine
The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.
